EBV-positive PCNSL in older patients: incidence, characteristics, tumor pathology, and outcomes across a large multicenter cohort

References

• Han CH, Batchelor TT. Diagnosis and management of primary central nervous system lymphoma. Cancer. 2017;123(22):4314–4324.
   PubMed Web of Science ®Google Scholar
• Kasenda B, Ferreri AJM, Marturano E, et al. First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)—a systematic review and individual patient data meta-analysis. Ann Oncol. 2015;26(7):1305–1313.
   PubMed Web of Science ®Google Scholar
• Johnson AT, Nooruddin Z, King GT, et al. Single institution retrospective review of patients with primary CNS lymphoma (PCNSL). J Clin Oncol. 2016;34(15):E19078.
   Google Scholar
• Braggio E, Van Wier S, Ojha J, et al. Genome-wide analysis uncovers novel recurrent alterations in primary central nervous system lymphomas. Clin Cancer Res. 2015;21(17):3986–3994.
   PubMed Web of Science ®Google Scholar
• Shiels MS, Pfeiffer RM, Besson C, et al. Trends in primary central nervous system lymphoma incidence and survival in the U.S. Br J Haematol. 2016;174(3):417–424.
   PubMed Web of Science ®Google Scholar
• Crane GM, Powell H, Kostadinov R, et al. Primary CNS lymphoproliferative disease, mycophenolate and calcineurin inhibitor usage. Oncotarget. 2015;6(32):33849–33866.
   PubMed Web of Science ®Google Scholar
• Mahale P, Shiels MS, Lynch CF, et al. Incidence and outcomes of primary central nervous system lymphoma in solid organ transplant recipients. Am J Transplant. 2018;18(2):453–461.
   PubMed Web of Science ®Google Scholar
• Sugita Y, Furuta T, Ohshima K, et al. The perivascular microenvironment in Epstein-Barr virus positive primary central nervous system lymphoma: the role of programmed cell death 1 and programmed cell death ligand 1. Neuropathology. 2018;38(2):125–134.
   PubMed Web of Science ®Google Scholar
• O'Neill BP, Decker PA, Tieu C, et al. The changing incidence of primary central nervous system lymphoma is driven primarily by the changing incidence in young and middle‐aged men and differs from time trends in systemic diffuse large B‐cell non‐Hodgkin’s lymphoma. Am J Hematol. 2013;88(12):997–1000.
   PubMed Web of Science ®Google Scholar
• Kleinschmidt-DeMasters BK, Damek DM, Lillehei KO, et al. Epstein Barr virus-associated primary CNS lymphomas in elderly patients on immunosuppressive medications. J Neuropathol Exp Neurol. 2008;67(11):1103–1111.
   PubMed Web of Science ®Google Scholar
• Sugita Y, Muta H, Ohshima K, et al. Primary central nervous system lymphomas and related diseases: pathological characteristics and discussion of the differential diagnosis. Neuropathology. 2016;36(4):313–324.
   PubMed Web of Science ®Google Scholar
• MacMahon EM, Glass JD, Hayward SD, et al. Epstein-Barr virus in AIDS-related primary central nervous system lymphoma. Lancet. 1991;338(8773):969–973.
   PubMed Web of Science ®Google Scholar
• Sugita Y, Terasaki M, Niino D, et al. Epstein–Barr virus-associated primary central nervous system lymphomas in immunocompetent elderly patients: analysis for latent membrane protein-1 oncogene deletion and EBNA-2 strain typing. J Neurooncol. 2010;100(2):271–279.
   PubMed Web of Science ®Google Scholar
• Deangelis LM, Wong E, Rosenblum M, et al. Epstein‐Barr virus in acquired immune deficiency syndrome (AIDS) and non‐AIDS primary central nervous system lymphoma. Cancer. 1992;70(6):1607–1611.
   PubMed Web of Science ®Google Scholar
• Jamal SE, Li S, Bajaj R, et al. Primary central nervous system Epstein–Barr virus-positive diffuse large B-cell lymphoma of the elderly: a clinicopathologic study of five cases. Brain Tumor Pathol. 2014;31(4):265–273.
   PubMed Web of Science ®Google Scholar
• Mahadeva A, Rao CR, Shanmugham M, et al. Primary central nervous system diffuse large B-cell lymphoma in the immunocompetent: immunophenotypic subtypes and Epstein-Barr virus association. J Neurosci Rural Pract. 2015;6(1):8–14.
   PubMedGoogle Scholar
• Sharma MC, Gupta RK, Kaushal S, et al. A clinicopathological study of primary central nervous system lymphomas and their association with Epstein-Barr virus. Indian J Med Res. 2016;143:605–615.
   PubMed Web of Science ®Google Scholar
• Kitai R, Matsuda K, Adachi E, et al. Epstein-Barr virus-associated primary central nervous system lymphoma in the Japanese population. Neurol Med Chir. 2010;50(2):114–118.
   PubMed Web of Science ®Google Scholar
• Castillo JJ, Beltran BE, Miranda RN, et al. EBV‐positive diffuse large B‐cell lymphoma of the elderly: 2016 update on diagnosis, risk‐stratification, and management. Am J Hematol. 2016;91:529–537.
   PubMed Web of Science ®Google Scholar
• Rezk SA, Weiss LM. Epstein-Barr virus–associated lymphoproliferative disorders. Hum Pathol. 2007;38(9):1293–1304.
   PubMed Web of Science ®Google Scholar
• Fink SEK, Gandhi MK, Nourse JP, et al. A comprehensive analysis of the cellular and EBV‐specific microRNAome in primary CNS PTLD identifies different patterns among EBV‐associated tumors. Am J Transplant. 2014;14(11):2577–2587.
   PubMed Web of Science ®Google Scholar
• Sundin A, Grzywacz BJ, Yohe S, et al. B-cell posttransplant lymphoproliferative disorder isolated to the central nervous system is Epstein-Barr virus positive and lacks p53 and Myc expression by immunohistochemistry. Hum Pathol. 2017;61:140–147.
   PubMed Web of Science ®Google Scholar
• Kerr JR. Epstein-Barr virus (EBV) reactivation and therapeutic inhibitors. J Clin Pathol. 2019;72:651–658.
   PubMed Web of Science ®Google Scholar
• Ressing ME, van Gent M, Gram AM, et al. Immune evasion by Epstein-Barr virus. Curr Top Microbiol Immunol. 2015;391:355–381.
   PubMed Web of Science ®Google Scholar
• Yin H, Qu J, Peng Q, et al. Molecular mechanisms of EBV-driven cell cycle progression and oncogenesis. Med Microbiol Immunol. 2019;208(5):573–583.
   PubMed Web of Science ®Google Scholar
• Louis DN, Perry A, Wesseling P, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021;23(8):1231–1251.
   PubMed Web of Science ®Google Scholar
• O'Neill BP, Vernino S, Dogan A, et al. EBV-associated lymphoproliferative disorder of CNS associated with the use of mycophenolate mofetil. Neuro-oncology. 2007;9(3):364–369.
   PubMed Web of Science ®Google Scholar
• Caillard S, Dharnidharka V, Agodoa L, et al. Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression. Transplantation. 2005;80(9):1233–1243.
   PubMed Web of Science ®Google Scholar
• Opelz G, Döhler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant. 2004;4(2):222–230.
   PubMed Web of Science ®Google Scholar
• Martínez AJ. The neuropathology of organ transplantation: comparison and contrast in 500 patients. Pathol Res Pract. 1998;194(7):473–486.
   PubMed Web of Science ®Google Scholar
• Nicolae A, Pittaluga S, Abdullah S, et al. EBV-positive large B-cell lymphomas in young patients: a nodal lymphoma with evidence for a tolerogenic immune environment. Blood. 2015;126(7):863–872.
   PubMed Web of Science ®Google Scholar
• Beltran BE, Morales D, Quiñones P, et al. EBV-positive diffuse large B-cell lymphoma in young immunocompetent individuals. Clin Lymphoma Myeloma Leuk. 2011;11(6):512–516.
   PubMed Web of Science ®Google Scholar
• Kim JH, Cho H, Sung H, et al. Reappraisal of the prognostic value of Epstein-Barr virus status in monomorphic post-transplantation lymphoproliferative disorders–diffuse large B-cell lymphoma. Sci Rep. 2021;11:2880.
   PubMed Web of Science ®Google Scholar
• Park S, Lee J, Ko YH, et al. The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma. Blood. 2007;110(3):972–978.
   PubMed Web of Science ®Google Scholar
• Keane C, Tobin J, Gunawardana J, et al. The tumour microenvironment is immuno-tolerogenic and a principal determinant of patient outcome in EBV-positive diffuse large B-cell lymphoma. Eur J Haematol. 2019;103(3):200–207.
   PubMed Web of Science ®Google Scholar
• Lu TX, Liang JH, Miao Y, et al. Epstein-Barr virus positive diffuse large B-cell lymphoma predict poor outcome, regardless of the age. Sci Rep. 2015;5:12168.
   PubMed Web of Science ®Google Scholar
• Sato A, Nakamura N, Kojima M, et al. Clinical outcome of Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly in the rituximab era. Cancer Sci. 2014;105(9):1170–1175.
   PubMed Web of Science ®Google Scholar
• Gandhi MK, Hoang T, Law SC, et al. EBV-associated primary CNS lymphoma occurring after immunosuppression is a distinct immunobiological entity. Blood. 2021;137(11):1468–1477.
   PubMed Web of Science ®Google Scholar
• Kreher S, Jöhrens K, Strehlow F, et al. Prognostic impact of B-cell lymphoma 6 in primary CNS lymphoma. Neuro-oncology. 2015;17(7):1016–1021.
   PubMed Web of Science ®Google Scholar
• Lossos C, Bayraktar S, Weinzierl E, et al. LMO2 and BCL6 are associated with improved survival in primary central nervous system lymphoma. Br J Haematol. 2014;165(5):640–648.
   PubMed Web of Science ®Google Scholar
• Evens AM, Choquet S, Kroll‐Desrosiers AR. Primary CNS posttransplant lymphoproliferative disease (PTLD): an international report of 84 cases in the modern era. Am J Transplant. 2013;13(6):1512–1522.
   PubMed Web of Science ®Google Scholar
• Kempf C, Tinguely M, Rushing EJ. Posttransplant lymphoproliferative disorder of the central nervous system. Pathobiology. 2013;80(6):310–318.
   PubMed Web of Science ®Google Scholar